Effect of atorvastatin versus no Statin Treatment on major clinical events in Acute CardioEmbolic stroke patients without a definite indication for statin therapy: protocol for the STACE trial

 Why is there discussion on this? Didn't this earlier research prove the benefit of immediate statin therapy? Or do you INCOMPETENTLY NOT KNOW ABOUT IT?

Association Between Acute Statin Therapy, Survival, and Improved Functional Outcome After Ischemic Stroke: The North Dublin Population Stroke Study March 2011

Or don't you have a functioning stroke doctor who incompetently missed this research from 2011?

1. Statins.

tested in rats from 2003

http://Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke  

Simvastatin Attenuates Stroke-induced Splenic Atrophy and Lung Susceptibility to Spontaneous Bacterial Infection in Mice

Or,

Simvastatin attenuates axonal injury after experimental traumatic brain injury and promotes neurite outgrowth of primary cortical neurons 

October 2012

tested in humans, March 2011

http://www.medwirenews.com/39/91658/Stroke/Acute_statin_therapy_improves_survival_after_ischemic_stroke.html

And now lost even to the Wayback Machine

So, I think this below is the actual research.

Association Between Acute Statin Therapy, Survival, and Improved Functional Outcome After Ischemic Stroke April 2011 

The latest here:

CardioEmbolic stroke patients without a definite indication for statin therapy: protocol for the STACE trial

• Hong-Kyun Park, 
• Jun Yup Kim, 
• Keun-Sik Hong, 
• Yong-Jin Cho, 
• Jong-Moo Park, 
• Dongwhane Lee, 
• Kyusik Kang, 
• Soo Joo Lee, 
• Jae Guk Kim, 
• Jae-Kwan Cha, 
• Dae-Hyun Kim, 
• Moon-Ku Han, 
• Beom Joon Kim, 
• Jihoon Kang, 
• Tai Hwan Park, 
• Sang-Soon Park, 
• Jin Kyo Choi, 
• Kyungbok Lee, 
• Jeong-Yoon Lee, 
• Jun Lee, 
• Doo Hyuk Kwon, 
• Byung-Chul Lee, 
• Kyung-Ho Yu, 
• Mi Sun Oh, 
• …
• Hee-Joon Bae 

Trials volume 26, Article number: 358 (2025) Cite this article

Evidence supporting the use of statin therapy to reduce stroke recurrence and cardiovascular events in acute cardioembolic stroke (CES) patients without atherosclerosis is limited. Past observational studies have been hampered by selection bias and unmeasured confounding factors. This study aims to investigate the potential benefits of statin therapy in acute CES patients without established indications through a registry-based, randomized clinical trial.

Methods

This is a registry-based, multicenter, prospective, randomized, open-label, blinded endpoint (PROBE) study designed to evaluate the efficacy and safety of statin therapy in acute CES patients without established indications for statin use. Patients will be randomly assigned (1:1) to either statin users or non-users, with statin users receiving atorvastatin at a dose of 10 mg or higher throughout the study period. We plan to recruit 1036 participants to detect a relative risk reduction of 43% with 80% power and a two-sided alpha error of 0.05, accounting for a 10% loss to follow-up. The primary outcome is the occurrence of a major clinical event, defined as a composite of stroke recurrence, myocardial infarction, and all-cause mortality within 3 months after the index stroke. The secondary efficacy outcomes include (1) stroke recurrence, (2) all-cause mortality, (3) vascular death, and (4) major vascular events.

Discussion

This study will assist stroke physicians in determining the appropriate use of statin therapy for acute CES patients who do not have guideline-based indications.

Trial registration

CRIS Registration Number: KCT0006806. Registered on November 29, 2021. URL: https://cris.nih.go.kr/cris

Peer Review reports